In the world of biopharma R&D, an industry where clinical failure is often terminal, every strategic challenge is fundamentally underpinned by a technical understanding of probability of success. Be it determining the ‘best’ clinical development strategy of a single asset or anticipating the drugability of diseases in the future through developments in basic science today. Therefore, scientific & clinical understanding drives the viable business strategies most likely to bring value to patients, drug developers and society.

Graham has been enamoured with these complex problems throughout the entirety of his career leading to him constantly innovate tailored solutions for his clients unique situations and, more recently with the other founding partners of Scitaris, bring together a group of highly talented and experienced individuals who deliver unparalleled depth of insight leading to accurate and robust strategic conclusions.

During his time in biopharma R&D strategy Graham has led a wide range of projects both at a corporate and asset-level. Examples include the strategic prioritisation of drug modalities to maximise both mid- & long-term value, the development of a science-led BD&L / M&A search, introducing ‘gold-standard’ due-diligence and evaluation processes as well as the identification of high-value targets for various pre-C assets. Before this he gained his PhD in Newcastle, UK where he was the first to show that DnaA, the master initiator of DNA replication in prokaryotes, formed a helical structure in vivo that is likely the driver of its fundamental activity and the key regulated rate-limiting step in initiation.